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A B S T R A C T
The miR-451 was found to be frequently down-regulated in tumors, indicating that miR-451 could play
an important role in carcinogenesis. This study uncovered the mechanism by which the miR-451
functions as a tumor suppressor. The target genes of miR-451 were determined using target gene
prediction softwares. Then the miR-451 mimics were introduced into RKO and Hela cells respectively.
The proliferation and invasion of cells were monitored by MTT, cell cycle and in vitro extracellular matrix
invasion assays. Also the angiogenesis of HUVEC cells transfected with miR-451 mimics was examined.
Subsequently, IL6R, a predicted target gene of miR-451, was studied by real time PCR, Western blotting,
and siRNA technologies. The mRNA and protein levels of IL6R gene were found to be down-regulated in
the RKO and Hela cells transfected with miR-451 mimics. Consequently, the cell proliferation was
inhibited. Also, the invasion of RKO cells was suppressed. Furthermore, the angiogenesis of HUVEC cells
transfected with miR-451 mimics was assayed and the decreased angiogenic ability was detected
compared to the controls. All these results were validated by IL6R siRNA experiments. The IL6R gene is a
target gene of miR-451. The miR-451 behaves as a tumor suppressor, probably by targeting the IL6R
pathway.
 2013 Elsevier Ltd. All rights reserved.
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jou r nal h o mep age: w ww.c an cer ep idem io log y.n et1. Introduction
Most oncogenes and tumor-suppressor genes are ﬁrst tran-
scribed from DNA into RNA, and then translated into proteins to
exert their effects. Increasing evidence indicates that small non-
coding RNA molecules, called microRNA (miRNAs), can also
function as tumor suppressors and oncogenes [1]. The miRNAs
are short, endogenous, non-coding RNAs known to inhibit the
translation of their target transcripts and have wide range of roles
in differentiation, development, growth and apoptosis [2]. In
mammals, miRNAs are transcribed by RNA polymerase II as
primary-miRNA (pri-miRNA) [3]. The pri-miRNA is cleaved by the
Drosha ribonuclease III enzyme to generate an approximately 70-
nt stem-loop precursor miRNA (pre-miRNA), which is exported
into the cytoplasm by the transporter exportin 5 [4]. Subsequently,§ This project was supported by the Huazhong University of Science and
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http://dx.doi.org/10.1016/j.canep.2013.12.005it is further cleaved by the Dicer ribonuclease to produce the
mature miRNA and antisense miRNA star (miRNA*) products [5].
The mature miRNA is incorporated into a RNA-induced silencing
complex (RISC), which most commonly results in translational
inhibition or destabilization of the target mRNAs [6,7].
In cells, miRNAs regulate gene expression in a speciﬁc and
effective manner. This regulation is considered to be economic and
energy saving. Consequently, miRNAs is involved in many
processes in cells. The miRNA-451 (miR-451) gene is located at
17q11.2. It has been found to be expressed in many human tissues,
and showed a high expression level in fetuses compared to adults
[8–10]. Specially, the miR-451 has 5 variants, indicating that it
could play a major role in cell growth and differentiation [9].
However, miR-451 exhibited a lower expression level in several
cancers [11–13], suggesting that it may be engaged in the
carcinogenesis. It is of interest to understand how the miR-451
functions in tissue cells or cancers, namely what its target genes
are. To date only few studies have reported on the mechanism of
miR-451 in gene expression regulation.
In the present study, we investigated relationship between
miR-451 and its candidate target gene IL6R in human colon
carcinoma cell line RKO, human cervical cancer cell line Hela and
human umbilical vein endothelial cells (HUVEC). After transfecting
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investigated the expression of the IL6R proteins in RKO and Hela
cells. Taking together, we found that transfection of miR-451
down-regulated IL6R expression at both mRNA and protein level.
Finally, we found that the transfection of miR-451 suppressed cell
proliferation and invasion and angiogenesis. These ﬁndings gave
new insights into the roles of miR-451 in tumourigenesis.
2. Materials and methods
2.1. Target gene prediction
Mature miR-451 sequence was obtained from miRBase (http://
www.mirbase.org/). Five web-based miRNA target prediction
programs were used for the prediction of miR-451 potential target
genes: TargetScans (http://www.targetscan.org/index.html), DIANA
LAB (http://diana.cslab.ece.ntua.gr/microT/), microRNA.org (http://
www.microrna.org/microrna/home.do), PicTar (http://pictar.mdc-
berlin.de/), Microcosm Targets (http://www.ebi.ac.uk/enright-srv/
microcosm/cgi-bin/targets/v5/search.pl). The candidate target
genes were chosen based on high miRNA:mRNA alignment scores
[14,15].
2.2. Cell lines and cell culture
The RKO, Hela and HUVEC cell lines were purchased from
Chinese Academy of Sciences (China). The RKO and Hela cells were
maintained in MEM medium (Hyclone, USA) supplemented with
10% fetal bovine serum (FBS) (Hyclone, USA), 1 mM sodium
pyruvate (Hyclone, USA), 1.5% sodium bicarbonate (Hyclone, USA)
and 100 units/ml penicillin/streptomycin (Invitrogen, USA). The
HUVEC cells were cultured in RMPI 1640 (Hyclone, USA)
supplemented with 10% FBS (Hyclone, USA) and 100 units/ml
penicillin/streptomycin (Invitrogen, USA). These cells were incu-
bated at 37 8C in a humidiﬁed chamber containing 5% CO2
atmosphere. It was routinely passaged at 1–2 day intervals.
2.3. Oligonucleotide synthesis and transfection
The mimics for miR-451 wildtype and variant, and IL6R-siRNA
were chemically synthesized by Ruibo company (China). Their
sequences were shown in Table 1. The RKO, Hela and HUVEC cells
were seeded into each well of 6-well plates respectively, and
incubated in antibiotic-free medium overnight. The oligonucleo-
tides above were then transfected into RKO and Hela cells
respectively using Lipofectamine 2000 reagent (Invitrogen, USA)
at the time of 40–50% conﬂuence. According to the manufacturer’s
instructions, the transfection complexes containing 100 nmol ofTable 1
The oligonucleotide sequences used in the study.
Oligonucleotide Sequen
Forward primer for IL6R RT-PCR CTC CT
Reverse primer for Il6R RT-PCR TCT TG
Forward primer for GAPDH RT-PCR GAG TC
Reverse primer for GAPDH RT-PCR TTG AT
Forward primer for miR-451 RT-PCR AAA CC
Reverse primer for miR-451 RT-PCR CGC TA
U6 forward primer for RT-PCR CGC TT
U6 reverse primer for RT-PCR AAA AT
miR-451 wildtype mimic AAA CC
miR-451 variant mimic ACA CC
IL6R-siRNA (si-IL6R) CCA CG
Negative control miRNA (NTC M) UUU G
Negative control siRNA (NTC S) UUC UC
RT primer CGC TAoligonucleotides were added directly to the cells. At 4–6 h after
transfection, the medium was replaced with fresh MEM or
RPMI1640 containing 10% FBS, and the cells were incubated for
an additional 48 h and then harvested.
2.4. RNA isolation and PolyA reverse transcription
The small RNAs (200 nt) were isolated from the RKO and Hela
using a mirVanaTM miRNA isolation kit (Ambion, USA) following
the manufacturer’s instructions. The small RNAs were eluted in
100 ml RNase-free water. The RNA concentration was tested by UV
absorbance at 260 nm. The small RNAs were polyadenylated at
37 8C for 30 min in 50 ml reaction volume using 5 mg RNA and 5 U
poly(A) polymerase (New England Biolabs, USA). Then the poly(A)-
tailed small RNAs were puriﬁed through phenol/chloroform
extraction and ethanol precipitation. Reverse transcription was
conducted using the entire poly(A)-tailed RNA and 10 mM RT
primer (50-CGC TAC GTA ACG GCA TGA CAG TG(T)24-30) (Table 1)
with 200 U of SuperScript III reverse transcriptase (Invitrogen,
USA) according to the manufacturer’s instructions.
2.5. Assessment of the endogenous and transfected miRNAs by
quantitative PCR
Real-time PCR was carried out in a ABI StepOnePlus system with
the miRNA-speciﬁc forward primers (50-AAA CCG TTA CCA TTA CTG
AGT T-30) and reverse primer (50-CGC TAC GTA ACG GCA TGA CAG
TG-30) (Table 1), and TransStart SYBR green qPCR supermix
(TransGen, Biotech) following the manufacturer’s instructions. The
20 ml reaction mixture including 0.5 ml of cDNA synthesized
above, 10 ml TransStart SYBRgreen qPCR supermix and 0.5 mM
forward and reverse primers was incubated at 95 8C for 5 min,
followed by 40 cycles of 95 8C for 10 s, 55 8C for 15 s and 72 8C for
20 s. Melting curves for each PCR were carefully monitored to
avoid non-speciﬁc ampliﬁcation. The U6 small nuclear RNA was
used as the internal control. The primers used were shown in
Table 1. Each sample was analyzed in triplicate. The relative level
(RL) of each miRNA expression was calculated with 2DDCtmethod.
2.6. Analysis of IL6R mRNA by quantitative RT-PCR
Total RNAs were isolated from RKO and Hela using TRIZol1
Reagent (Invitrogen, USA) following the manufacturer’s instruc-
tions, and the total RNAs were eluted in 50 ml RNAse-free water.
The RNA concentration was tested by UV absorbance at 260 nm.
The total RNAs were reverse transcribed using RevertAid First
Strand cDNA Synthesis Kit (Thermo Scientiﬁc, USA) following the
manufacturer’s instructions. Real-time PCR was carried out in ance
G CCA GTT AGC AGT CC
C CAG GTG ACA CTG AG
A ACG GAT TTG GTC GTC
T TTG GAG GGA TCT CG
G TTA CCA TTA CTG AGT T
C GTA ACG GCA TGA CAG TG
C GGC AGC ACA TAT AC
A TGG AAC GCT TCA CGA
G UUA CCA UUA CUG AGU U
G UUA CCA UUA CUG AGU UU
A CUC UGG AAA CUA U dTdT
UA CUA CAC AAA AGU ACU G
C GAA CGU GUC ACG UUC UG
C GTA ACG GCA TGA CAG TG(T)24
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CTC CTG CCA GTT AGC AGT CC-30) and reverse primer (50-TCT TGC
CAG GTG ACA CTG AG-30) (Table 1), and TransStart SYBR green
qPCR supermix (TransGen, China) following the manufacturer’s
instructions. The 20 ml reaction mixture including 0.5 ml of cDNA,
10 ml TransStart SYBRgreen qPCR supermix and 0.5 mM forward
and reverse primers was incubated at 95 8C for 5 min, followed by
40 cycles of 95 8C for 10 s, 55 8C for 15 s and 72 8C for 20 s. Melting
curves for each PCR were carefully monitored to avoid non-speciﬁc
ampliﬁcation. The expression level of IL6R mRNA was normalized
by glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expres-
sion with 2DDCt method. The primers for amplifying GAPDH were
listed in Table 1. Each sample was analyzed in triplicate.
2.7. Western blotting analysis
The harvested RKO and Hela cells were lysed in RIPA lysis buffer
with protease inhibitors (1 mM PMSF) to isolate proteins, which
were quantiﬁed using the BCA protein assay (Aidlab, China). Equal
amounts of protein samples (40 mg) were separated on a 12%
SDS-PAGE and electrophoretically transferred onto PVDF mem-
brane (Millipore, USA). After blocking with 5% non-fat milk in TBS-
Tween-20 for 5 h at room temperature, the membranes were
blotted with the appropriate primary IL6R antibody (GeneTex,
USA) at a 1:500 dilution overnight at 4 8C. After TBST washing, the
membranes were incubated with the secondary anti-rabbit
antibody linked to horseradish peroxidase at a 1:5000 dilution
for 1.5 h at room temperature. The protein expression level was
normalized with GAPDH (Abcam, USA). After TBST washing, the
speciﬁc binding antibody was detected using the enhanced
chemiluminescent assay (BeyoECLPlus, China) according to the
manufacturer’s protocol. Each sample was assayed in three
independent experiments. The intensity of the bands was
examined by using QUANTITY ONE 4.62 (Bio-Rad, USA).
2.8. Cell proliferation MTT assay
The RKO and Hela cells were seeded into 96 well plates at a
density of 5.0  103 cells per well with six replicates, respectively.
At 24, 48, and 72 h after transfection, 10 ml MTT (Sigma, USA)
reagent was added to each well, and the mixture was incubated for
4 h. After the incubation, the supernatant was removed and 100 ml
dimethl sulfoxide (DMSO) was added to dissolve the formazan
crystals. Optical density (OD) value of each sample was measured
at a wavelength of 490 nm on a Microplate Reader (UNRISE TECAN,
Switzerland). The cell proliferation rate was measured by the
following formula: (AM  AC)/AC  100%, where AC means
absorbance value of the negative control groups and AM means
absorbance value of the experimental groups.
2.9. Cell cycle assay by ﬂow cytometry
The RNA oligonucleotides were transfected to RKO cells grown
in 6-well plate for ﬂow cytometry assay. At 24 h after transfection,
the cells were re-plated into three wells. Then, additional 24 h later
the cells were harvested for ﬂow cytometry assay. Cells were
washed with phosphate-buffered saline (PBS) before ﬁxation in
ethanol. The ﬁxed cells were treated with 20 mg/ml DNase-free
RNaseA in PBS at 37 8C for 30 min, stained with propidium iodide
(PI) at room temperature for 5 min. The ratio of cells in different
stages of cell cycle was analyzed by ﬂow cytometry.
2.10. In vitro extracellular matrix invasion assays
The cancer cell invasion in vitro was demonstrated using 24-
well transwell units (Corning, USA) with a 8 mm pore sizepolycarbonate ﬁlter coated with Matrigel1 (matrigel basement
Membrane USA) to form a continuous thin gel. The RKO Cells
(4  105) maintained in serum-free medium containing 0.1% BSA
were added to the upper chamber. The lower chamber contained
500 ml MEM medium with 10% FBS. Cells were incubated for 24 h
at 37 8C, 5% CO2 incubator. Then cells on the upper surface of the
ﬁlter were completely removed with a cotton swab. The ﬁlters
were ﬁxed in methanol and stained with Hematoxylin Staining
Solution. Cells that invaded the matrigel and reached the lower
surface of the ﬁlters were counted under microscopy at a
magniﬁcation of 100. Each experiment was repeated in triplicate.
2.11. In vitro angiogenesis assay
The angiogenic ability was assessed using Matrigel1 assay and
in vitro angiogenesis assay on Matrigel1 culture. The HUVEC cells
were transfected as described above. At 24 h after transfection the
HUVEC cells were seeded on Matrigel1 pre-coated 96-well plate at
a density of 5  104 cells per well. The angiogenic ability was
assessed at 8 h after plating on Matrigel1, through vessels count/
size calculated by Image PRO-Plus 6.0.
2.12. Statistical analysis
A two-tailed Student’s t test was used to analyze differences
between the parameters. P  0.05 was regarded as a signiﬁcant
difference.
3. Results
3.1. IL6R gene was chosen to be studied
Based on high scores of miRNA:mRNA alignment through ﬁve
software tools, 4 genes were chosen for further analysis: EMSY, IL6R,
OSR1, and YTHDF2. After being examined rapidly by RT-PCR and
realtime PCR, the IL6R gene was regarded as a potential target gene
of miR-451. The 50 bases 2–7 of miR-451, the seed region of miRNAs,
matches completely with 30 UTR region of IL6R mRNA (Fig. 1A).
3.2. Low level of endogenous miR-451 and high efﬁciency of
transfection of miRNA mimics
The expression level of endogenous miR-451 in both RKO
and Hela was examined using real-time PCR. A low level of miR-
451 was detected in both cell lines (P < 0.001, Fig. 1B and C).
The miRNA mimics were transfected into both cell lines, and a
high efﬁciency of transfection was identiﬁed (Fig. 1B and C).
3.3. The IL6R gene was knocked down in both mRNA and protein levels
The mRNA and protein levels of the IL6R gene were analyzed in
the RKO and Hela cells after transfections with miR-451 mimics. A
signiﬁcant inhibition was seen in both mRNA and protein levels
(P < 0.001, Figs. 2 and 3). Interestingly, the miR-451 variant does
not suppress IL6R gene even though there is only one base
difference in the seed sequence between the wild type and the
variant (Table 1).
3.4. The miR-451 inhibited cell proliferation, invasion and
angiogenesis
The transfected RKO and Hela were tested for cell proliferation
rate by MTT experiments. The relative proliferation rates for cells
transfected with miR-451 mimics were signiﬁcantly lower than
the controls (P < 0.001, Fig. 4). Furthermore, the cell cycle assay
was performed in the RKO cells. The increased cell percentages at
Fig. 2. Real-time PCR analysis of IL6R mRNA expression in RKO cell line (A) and Hela cell line (B) transfected with miR-451. The levels for negative controls (RKO and Hela)
were set as 100%. P < 0.001 between NTC M and miR-451 in RKO cells; P < 0.001 between NTC M and miR-451 in Hela cells. No difference was between NTC M and variant.
(RKO, 1.00  0.0240; NTC M, 0.96  0.0241; miR-451, 0.39  0.0105; Variant, 0.97  0.0314; Hela, 1.00  0.0239; NTC M, 1.23  0.0301; miR-451, 0.31  0.0115; Variant,
1.17  0.0276).
Fig. 1. (A) The sequence of miR-451 and alignment between miR-451 and mRNA of IL6R gene. (B) Quantitative PCR analysis of miR-451 level in RKO. (C) Quantitative PCR
analysis of miR-451 level in Hela. RKO, no transfection; Hela, no transfection; NTC M, negative control miRNA; whose level was set as 100%. P < 0.001 between RKO and miR-
451; P < 0.001 between Hela and miR-451. (RKO, 1.00  0.0251; NTC M, 1.23  0.0307; miR-451, 18.30  0.463; Variant, 22.60  0.565; Hela, 1.00  0.0248; NTC M,
1.78  0.0461; miR-451, 31.60  0.791; Variant, 46.30  1.158).
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seen for miR-451 mimics compared to controls (P < 0.001, Fig. 4).
The invasive properties of the RKO cell line were assayed using
transwell units. The relative invasion values for miR-451 mimics
were signiﬁcantly decreased compared to controls (P = 0.001,
Fig. 5). Moreover, the impact of miR-451 on the angiogenic ability
of the HUVEC cells was analyzed. The angiogenic ability for miR-
451 mimic transfected cells was signiﬁcantly lower than controls
(P = 0.006, Fig. 6).3.5. The siRNA experiments validated results on miRNAs
The RNA oligonucleotides with homology to the coding region
of IL6R gene were transfected into both RKO and Hela cells. The
IL6R proteins were then tested by Western blotting, and an obvious
inhibition of expression was seen compared to controls (Fig. 7).
Consequently the cell cycle and proliferation, invasion and
angiogenesis were assayed. The results were in line with those
on miRNAs (Figs. 4–6).
Fig. 3. Western blotting analysis of the IL6R protein in RKO (A) and Hela (B) transfected with miR-451. GAPDH was used as an internal control. The levels for negative controls
(RKO and Hela) were set as 100%. P < 0.001 between NTC M and miR-451 in the RKO cells; P < 0.001 between NTC M and miR-451 in the Hela cells. No statistical difference
was detected between the NTC M and the variant. (RKO, 1.00  0.0264; NTC M, 1.11  0.0371; miR-451, 0.24  0.00554; Variant, 1.06  0.0264; Hela, 1.00  0.0254; NTC M,
1.02  0.0240; miR-451, 0.53  0.0132; Variant, 1.12  0.0289).
Fig. 4. Cell proliferation MTT assay in RKO (A) and Hela (B). Negative controls (RKO and Hela) were set as 100%. P < 0.001 between NTC M and miR-451, and P < 0.001 between
NTC S and si-IL6R in the RKO cells; P < 0.001 between NTC M and miR-451, and P < 0.001 between NTC S and si-IL6R in the Hela cells. (C) Cell cycle assay using ﬂow cytometry
revealed that miR-451 and si-IL6R suppressed cell cycle transition from G0–G1 to S. The percentages of cells increased in G0–G1 phases and decreased in S phases compared
to the negative controls. (G0–G1 RKO, 38.88  0.942%; NTC M, 41.43  1.03%; miR-451, 48.28  1.20%; Variant, 44.87  1.31%; si-IL6R, 54.70  1.38%; NTC S, 37.95  0.950%; S
RKO, 36.65  0.910%; NTC M, 38.71  0.677%; miR-451, 34.48  0.826%; Variant, 35.95  0.895%; si-IL6R, 25.26  0.631%; NTC S, 39.46  0.965%; G2-M RKO, 24.48  0.0632%; NTC
M, 19.86  0.491%; miR-451, 17.23  0.475%; Variant, 19.18  0.495%; si-IL6R, 20.04  0.541%; NTC S, 22.60  0.585%).
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The target genes of miR-451 have been explored by few
research groups so far. One article reported that CAB39 is a target
gene of miR-451, and that it may regulate the CAB39/AMPKpathway [16]. Another group described that miR-451 down-
regulation allows the expression of the direct target gene
macrophage migration inhibitory factor, which is involved in
the expression of COX2. In turn, COX2 allows Wnt activation,
which is essential for growth of cancer stem cells. It is conceivable
Fig. 5. In vitro cell invasion assay. (A) Representative photos of the RKO cells invading ﬁlters. RKO cells transfected with NTC M, miR-451, variant, si-IL6R and NTC S. (B) The
relative invasion value comparison. The number of cells invading ﬁlter for negative control RKO was set as 100%. P = 0.001 between NTC M and miR-451; P < 0.001 between
NTC S and si-IL6R. (RKO, 1.00  0.0204; NTC M, 1.06  0.0261; miR-451, 0.59  0.0142; Variant, 0.89  0.0293; si-IL6R, 0.29  0.00728; NTC S, 1.12  0.0289).
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that have not been detected so far.
In this study, we used software prediction and miR-451 mimic
transfection to identify a target gene of miR-451, and found that
IL6R is a candidate. The ﬁnding was conﬁrmed by siRNA
experiments. Introduction of miR-451 mimics into cells generated
inhibition of cell proliferation and invasion, and angiogenesis
(Figs. 4–6). Our results suggest that miR-451 acts as a tumor
suppressor by down-regulating expression of IL6R gene (Figs. 2 and
3). We introduced miR-451 mimics into two types of cells, RKO and
Hela, in which IL6R gene displays a relatively high expression.
Interestingly, the IL6R mRNA was expressed a reduced level in both
transfected cell lines compared to controls, suggesting that the
mimics facilitate the cleavage and degradation of the IL6R mRNA
(Fig. 2). For the siRNA studies, RNA oligonucleotides were directly
introduced into cells instead of using vector transfection. It
demonstrated a high efﬁciency of gene interference (Fig. 7).
Moreover, the mimics for a variant of miR-451 was tested
simultaneously, and we found that it does not target the IL6R
gene (Figs. 2 and 3). The difference between wildtype and variant
of miR-451 is only one base in the seed sequence (Table 1). It
reﬂects that each base of the seed sequences of miRNAs can be
critical for the speciﬁcity of the miRNAs. In our previous study,
several variants of the miR-451 were identiﬁed [9]. Therefore it is
possible that miR-451 family could target a broad range of genes.IL6R is involved in IL6-STAT3-HIF signaling pathway, which
plays a role in cell growth and carcinogenesis [17,18]. Badache
et al. [19] suggested certain differences in the invasion and the
proliferation pathways and that MAPK signaling is essential for
IL6-induced invasion potential in breast cancer cells. Further-
more, the angiogenesis can be modulated by the IL6/STAT3
pathway [20]. IL6, originally identiﬁed as a B-cell differentiation
factor, is a multifunctional cytokine that regulates the immune
response, haemopoiesis, the acute phase response and inﬂamma-
tion. IL6 is produced by various types of cells and inﬂuences
various cell types, and has multiple biological activities through
its unique receptor system. IL6 exerts its biological activities
through IL6R [21]. It can be inferred that the miR-451 may
interfere with IL6-STAT3-HIF pathway to regulate cell growth and
induce carcinogenesis, and inﬂuence MAPK pathway to increase
invasive properties of cancer cells. Our study showed that
angiogenesis was inhibited by miR-451 (Fig. 6). The mechanism
behind this could be that the IL6/STAT3 pathway associated with
angiogenesis is targeted by miR-451. Therefore, targeting these
signaling circuits represents an effective therapeutic avenue for
cancer prevention and treatment.
In conclusion, the IL6R was veriﬁed to be a target gene of the
miR-451, which suppressed cell proliferation and invasion and
angiogenesis, probably by down-regulating the expression of the
IL6R gene.
Fig. 6. In vitro angiogenesis assay. (A) The angiogenic ability. HUVEC cells transfected with NTC M, miR-451, variant, si-IL6R and NTC S. (B) The relative count/size values. The
angiogenic ability was assessed through vessels count/size calculated by Image PRO-Plus 6.0. The angiogenesis for miR-451 and si-IL6R was obviously suppressed compared
to controls (P = 0.006). (HUVEC, 1.00  0.0267; NTC M, 1.04.0296; miR-451, 0.25  0.00658; Variant, 0.48  0.0152; si-IL6R, 0.08  0.00175; NTC S, 0.72  0.0178)
Fig. 7. Western blot analysis of the IL6R protein in RKO (A) and Hela (B) transfected with si-IL6R (IL6R-siRNA). NTC S, negative control siRNA. GAPDH was used as an internal
control. P < 0.001 between NTC S and miR-451 in the RKO cells; P < 0.001 between NTC S and miR-451 in the Hela cells. (RKO, 1.00  0.0271; NTC S, 1.10  0.0237; si-IL6R,
0.15  0.00359; Hela, 1.00  0.0271; NTC S, 0.90  0.0234; si-IL6R, 0.11  0.00227).
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